>>> US Gapping down


Gapping down
In reaction to disappointing earnings/guidance
: PMTS -38.6%, ACAT -11.5%, AEG -10.7%, AGI -5.9%, KSS -5.9%, CVO -5.6%, NMM -4.2%, EGO -3.5%, ONTX -3.4%, STAA -2.2%, ALXA -2.1%, USAT -0.5%

M&A news: YY -5.9% (Group of China investors have ended plans to purchase YY, according to WSJ)

Select Chinese ADRs showing weakness after YY news (see M&A section above) : VNET -5.5%, KANG -4.4%, QIHU -3.8%, DANG -3.8%, JMEI -2.8%, MOMO -2%

Select metals/mining stocks trading lower: IAG -3.6%, EGO -3.5%, AUY -2.5%, NEM -1.9%, RIO -1.2%, GFI -0.9%, SLV -0.8%, .

Other news: LNCO -56.4% (Linn Energy and LinnCo (LNCO) file voluntary petitions for restructuring under Chapter 11 of the Bankruptcy Code ), LINE -54.7% (Linn Energy and LinnCo (LNCO) file voluntary petitions for restructuring under Chapter 11 of the Bankruptcy Code ), PARN -13.8% (prices 2.55 mln of its ordinary shares for ~$4.2 mln), GST -4.8% ( to offer 40 mln common shares in a public offering ), TERP -4.8% (files to delay Form 10-Q, previews Q1 results), CLB -3% (upsizes and prices 1,475,000 shares of its common stock for gross proceeds of ~$175 mln), GST -2.8% (to offer 40 mln common shares in a public offering), LOXO -2.4% (prices follow-on offering of 1,675,000 shares of common stock at $21.50 per share), JCP -0.5% (in sympathy with KSS earnings)

Analyst comments: GE -1% (resumed with a Underweight at JP Morgan)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: BSTG +35.7%, LXU +23%, JACK +10.8%, RVLT +9.5%, YRD +6.7%, CDXC +6.4%, SSRI +4.9%, RL +4.1%, MIDD +3.5%, NTES +2.9%, RDY +2.8%, HIMX +2.1%, DLA +2%, AER +1.9%, PBH +1.2%, CLLS +1%, NEOT +1%, PAAS +0.9%

M&A news:BLOX +17.6% (receives acquisition proposal from PE firm Thoma Bravo, according to Bloomberg), MON +13.7% (move attributed to M&A speculation with BASF (BASFY) as possible suitor; also reports Bayer (BAYRY) is mulling a bid)

Select EU financial related names showing strength: DB +1.9%, BCS +1.7% (upgraded - see below), BBVA +1.6%, ING +1.3%


Select oil/gas related names showing strength: SDRL +6.4%, RIG +2.6%, BP +2%, RDS.A +1.9%, MRO +1.9%

Other news: PBMD +15.8% (signs licensing agreement with Sydys to license CVac), BDSI +8.3% (BioDelivery Sciences signs a licensing agreement granting exclusive rights to devlop and commercialize Onsolis in the US to Collegium Pharma ) CHK +5.5% (enters into privately negotiated purchase and exchange agreements under which it has and will exchange shares of common stock for certain of its outstanding senior notes), POT +3.1% (in sympathy with MON), WTW +2.7% (Director Denis Kelly purchases 10,000 shares at prices from $12.14-12.22; shareholders elect Oprah Winfrey to Board), SCTY +2.5% (still checking), MOS +2.1% (in sympathy with MON), VRX +1.6% (Pershing Square Holdings releases Q1 letter to investors), IHG +1.2% (announced details of special dividend), AZN +1.1% (receives Orphan Drug Designation for Selumetinib), HZNP +0.9% (enters into a settlement and license agreement with Teligent (TLGT) to resolve pending patent litigation involving Pennsaid 2%)

Analyst comments: GPK +2.4% (initiated with a Conviction Buy at Goldman), BCS +1.7% (upgraded to Neutral from Underperform at Exane BNP Paribas), SNY +1.6% (upgraded to Overweight from Equal Weight at Barclays), BERY +0.8% (initiated with a Buy at Goldman)

>>> US Early premarket gappers

Early premarket gappers

Gapping up: PBMD +20.1%, JACK +10.5%, YRD +9.1%, BDSI +8.3%, SDRL +7.2%, MON +6.8%, SSRI +5%, SCTY +4.3%, CHK +4.1%, CA +4.1%, CDXC +2.8%, RDY +2.8%, RIG +2.2%, SNY +2.1%, BP +2%, HIMX +2%, AER +1.9%, NTES +1.9%, RDS.A +1.8%, BCS +1.7%, PAAS +1.7%, FCX +1.6%, BBVA +1.6%, SHPG +1.5%, VRX +1.4%, DB +1.4%, ING +1.3%, LC +1.2%, GSK +1.2%, IHG +1.2%, PBH +1.2%, CLLS +1%

Gapping down: LNCO -58.4%, GBIM -28.6%, GST -12.8%, AEG -10.5%, AGI -10.4%, PMTS -9.3%, KSS -6.5%, IAG -6.2%, CVO -5.6%, LOXO -4.4%, YY -4.2%, EGO -3.5%, ONTX -3.4%, AUY -3.1%, JMEI -2.8%, RGLD -2.7%, SINA -2.7%, STAA -2.2%, ALXA -2.1%, CLB -2%, NEM -1.6%, JCP -1.5%, GE -1.3%, RIO -1%, GFI -0.9%, SLV -0.8%, BBL -0.7%

>>> Ralph Lauren beats by $0.05, reports revs in-line --> +4%

Ralph Lauren beats by $0.05, reports revs in-line

  • Reports Q4 (Mar) earnings of $0.88 per share, $0.05 better than the Capital IQ Consensus of $0.83; revenues fell 0.7% year/year to $1.87 bln vs the $1.86 bln Capital IQ Consensus. The decline in reported net revenues was in line with the guidance provided in February of a 0-2% reported revenue decline and included ~110 basis points of negative impact from foreign currency effects. In constant currency, international net revenue rose 3% in the fourth quarter, offset by a 1% decline in the Americas that was due to proactive measures taken in the U.S. to clear end-of-season inventories related to the Fall season.
    • In Q4, wholesale segment sales decreased 5% on a constant currency basis and 6% on a reported basis to $942 million, primarily due to a decline in sales in North America.
    • Retail segment sales increased 7% on a constant currency basis and 6% on a reported basis to $889 million in the fourth quarter, driven by the benefit of a 53rd week of sales, new store expansion and e-commerce growth. On a 13-week to 13-week basis, consolidated comparable store sales decreased 5% in constant currency and 6% as reported during the fourth quarter.
    • Gross profit margin was 54.5%, which was 90 basis points lower than the prior year period, reflecting proactive measures taken in the U.S. to clear end-of-season inventories related to the Fall season, in addition to unfavorable foreign currency effects.
  • Co will guide Q1/FY17 at June 7 Investor Day.

(ZH) The S&P 500 Chart Shows A "December Swoon" Is Straight Ahead

The S&P 500 Chart Shows A "December Swoon" Is Straight Ahead


With the recent rally showing increasing signs of exhaustion and the market topping, traders have begun to wonder if the S&P500 will suffer the same fate in the coming months as it did in August 2015, and - more apropos - in December, when the S&P failed to make a new high before starting a more significant correction leg into January.
Two technicians who are convinced this is precisely the case, are UBS' Michael Riesner and Marc Muller, who say that after hitting the April 20th reaction high at 2111 and seeing initial weakness, they see the SPX moving into a minor trading low late last week as the basis for a short bounce into mid-May. From a price perspective this move should either make a lower high or best case re-test the April 20th high before seeing more significant weakness into the June/July time window. In other words, at least according to UBS, the market has at most 3-4 weeks before the next major swoon lower.

Here is what else the UBS duo expects:
With last Friday’s reaction low at 2039, we have growing evidence that our suggested minor trading low is in place, which in this case would represent a new pivotal support. On the indicator side, our fast momentum indicators have started turning bullish on oversold territory, which is normally the confirmation that a trading low is in place/forming. On the sector front, we have several key sectors siting on important support levels and on the sentiment side the AAII Bullish Consensus at only 22% has hit a quite low level. Although the neutral camp in the AAII survey is still quite elevated, such a low bullish consensus is usually the basis for a bounce.
However, our medium-term view has not changed. We continue to think that a potential bounce would be limited in price and time and actually just part of a distributive top building phase and complete our anticipated early Q2 top, which in more and more markets globally (Europe and Asia) is already in place.
On the sector side, we have seen particularly last week initial trend breaks/significant weakness, where a bounce into next week in technology, financials, biotech and Russell-2000 should only post a lower high, as the setup for more weakness. On the other hand we see strength in commodity themes as a sell on the back of our suggested USD rebound scenario into summer.
Together with intact sell signals in our daily trend work and in our weekly momentum indicators, we think a bounce into next week can have the same character as in December, which failed to make a new high before starting a more significant correction leg into January.

Conclusion: From a cyclical aspect, the Friday reaction low at 2039 represents a new pivotal support, which makes the 2039/2033 support zone and the VIX breakout level at 17 an even more significant breakout level. With a bounce into next week we can see a re-test of the April 10th high at 2111. On the downside, a break of 2039/2033 would give us clear evidence that our suggested early Q2 top is in place with initial support at 1990 to 1950 into June and more significant weakness into July.

>>> Cnova contemplates reorganization of its Brazilian activities within Via Var

Cnova contemplates reorganization of its Brazilian activities within Via Varejo, receives acquisition offer from parent Casino, Guichard-Perrachon (CGUSY) for $5.50/share
The co confirmed that it has entered into a Memorandum of Understanding with Via Varejo S.A. regarding a possible reorganization of its Brazilian subsidiary, Cnova Brazil, within Via Varejo. As a result of the reorganization, Cnova would receive ~97 mln of its own shares currently held by Via Varejo (21.9% of its share capital) and cash consideration ranging from $32-49 mln. In addition, Via Varejo would reimburse a debt currently held by Cnova Brazil equivalent to ~$127 mln
  • Separately, Cnova's parent company, Casino, Guichard-Perrachon (CGUSY), announced that it would make an offer to purchase the outstanding ordinary shares of Cnova from its public shareholders at a price of $5.50 per share. The intention to make such offer is currently subject to:
    • Cnova and Via Varejo reaching a binding agreement on the proposed reorganization and completing the proposed transaction,
    • The fulfilment, by the time the binding agreements are entered into, of certain conditions precedent (and notably the absence of material adverse event with respect to Cnova)
    • The commitment, by the time the binding agreements are entered into, of Companhia Brasileira de Distribuição (Cnova minority shareholder and part of Casino Group) not to participate in the offer.